Holiday book sale: Save up to 30% on print and eBooks. No promo code needed.
Save up to 30% on print and eBooks.
Clinical Studies and Therapies in Parkinson's Disease
Translations from Preclinical Models
1st Edition - June 12, 2021
Author: Juan Segura-Aguilar
9 7 8 - 0 - 1 2 - 8 2 2 1 2 0 - 4
9 7 8 - 0 - 1 2 - 8 2 2 1 5 8 - 7
More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson’s disease, but it remains the most common treatment despite inducing severe side… Read more
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson’s disease, but it remains the most common treatment despite inducing severe side effects such as dyskinesia after 4–6 years of use. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies for Parkinson’s disease, but these efforts have failed when attempting to transfer these successful results to preclinical studies. Although several publications have warned of these failures, the scientific community remains mostly unaware, and there is a need to focus their efforts on potential therapeutics that can slow or halt development of the disease.Clinical Studies and Therapies in Parkinson’s Disease: Translations from Preclinical Models analyzes preclinical models based on exogenous neurotoxins and why they have failed. Neuroscientists, neurologists, and neuropharmacologists will benefit greatly from the book’s discussion of these newer models, their benefits, and the need for their implementation. This book also provides the basic concepts of dopamine metabolism for students taking courses in neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine.
Reviews Parkinson's disease classification, pharmacological therapies, and nonmotor and motor symptoms
Analyzes preclinical models of Parkinson’s disease therapies based on exogenous neurotoxins and why they have failed
Reviews genetic preclinical models based on genetic mutations and endogenous neurotoxins
Proposes a more physiological model directly related to the metabolism of dopaminergic neurons
Provides the basic concepts and mechanisms of dopamine metabolism
Neuroscientists, neurologists, neuropharmarcologists, and students studying neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine
1. Parkinson’s disease
2. Parkinson´s pharmacological therapy
3. Dopamine synthesis
4. Dopamine storage and release
5. Dopamine oxidative deamination
6. Dopamine methylation
7. Dopamine oxidation to neuromelanin and neurotoxic metabolites
8. Neuroprotective mechanisms against dopamine oxidation-dependent neurotoxicity
9. Preclinical model based on exogenous neurotoxins for Parkinson's disease
10. Preclinical models based on genetic mutations associated with the familial form of Parkinson´s disease
11. Preclinical models based on endogenous neurotoxins
No. of pages: 306
Published: June 12, 2021
Imprint: Academic Press
Paperback ISBN: 9780128221204
eBook ISBN: 9780128221587
Dr. Juan Segura-Aguilar, PhD, is a professor of molecular and clinical pharmacology at the University of Chile, Santiago, Chile. He obtained his PhD in biochemistry from Stockholm University, Stockholm, Sweden in 1989. He was previously an associate professor at Uppsala University, Uppsala, Sweden. In 1998, he began as an associate professor at University of Chile, and since 2001 has been a full professor. His research has been focused on mechanisms involved in dopaminergic neuron degeneration in Parkinson´s disease. He has more than 140 publications of his research work on neurodegenerative disorders.